Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-04-14
2009-06-02
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S548000, C530S388260
Reexamination Certificate
active
07541159
ABSTRACT:
Antibodies have been developed against the different molecular forms of urokinase using synthetic peptides as immunogens. The peptides were synthesized specifically to represent those regions of the urokinase molecules which are exposed in the three-dimensional configuration of the molecule and are uniquely homologous to urokinase. Antibodies are directed against the lysine 158-isoleucine 159 peptide bond which is cleaved during activation from the single-chain (ScuPA) form to the bioactive double chain (54 KDa and 33 KDa) forms of urokinase and against the lysine 135 lysine 136 bond that is cleaved in the process of removing the alpha-chain from the 54 KDa form to produce the 33 KDa form of urokinase. These antibodies enable the direct measurement of the different molecular forms of urokinase from small samples of conditioned medium harvested from cell cultures.
REFERENCES:
patent: 4474756 (1984-10-01), Mitsuhashi et al.
patent: 4600580 (1986-07-01), Smith
patent: 4673573 (1987-06-01), Ferres et al.
patent: 4741903 (1988-05-01), Smith
patent: 4791068 (1988-12-01), Loskutoff et al.
patent: 4873083 (1989-10-01), Hunter et al.
patent: 5869238 (1999-02-01), Morrison
patent: 2005/0232924 (2005-10-01), Mazar et al.
Lederman et al, Molec. Immunol., 28, 1171-1181, 1991.
Morrison et al; Electrophoretic Separation of Kidney and Pituitary Cells on STS-8; Adv. Space Res.; vol. 4, No. 5, pp. 67-76, 1984, Great Britain.
Sibley et al; Enhancement Effect of Storage Buffer on Regeneration of Immunosorbent Surfaces; Benchmarks.
Verstraete et al; Pharmacology of Thrombolytic Drugs; JACC vol. 8, No. 6, Dec. 1986, pp. 33B-40B, Leuven, Belgium.
Barlow et al; Secretion of plasminogen actiator by the human macrophage-like cell line, GCT . . . ; British Journal of Haematology, 1982, 52, pp. 645-655.
Swank et al; Parallel line analysis: multifunctional software for the biomedical sciences; Computer Methods and Programs in Biomedicine, 33 (1990) pp. 95-105.
Barlow et al; Identification of the Plasminogen Activator(s) producted by the Transformed Liver Cell Line, SK-HEP-1; Thrombosis Research 32; 1983, pp. 29-34.
Schmitt et al; Tumour-associated fibrinolysis: the prognostic relevance of plaminogen activators uPA and tPA in . . . ; Blood Coagulation and Fibronolysis, 1990, pp. 695-702.
Hasui et al; Comparative Study of Plasminogen Activators in Cancers and Normal Mucosae of Human Unirary Bladder; Cancer Research 49, 1067-1070, Feb. 15, 1989.
Gaylis et al;Plasminogen Activators in Human Prostate Cancer Cell Lines and Tumors: Correlation with the Aggressive Phenotype; The Journal of Urology; vol. 142, 1989, pp. 193-198.
Verstraete et al; Thrombolytic Therapy in the Eighties; Journal of the American Society of Hematology; vol. 67, No. 6Jun. 1986, pp. 1539-1541.
Schmitz et al; Production of Monoclonal Antibodies with Pre-Selected Submolecular Binding Specificities to Protein . . . ; Molecular Immunology; vol. 19, No. 12, pp. 1699-1701.
Acton et al; Eukaryotic Cell Cultures Basics and Applications; Plenum Press; pp. 241-267.
Erickson; Metastatic Machinatiuns; Scientific American, Jul. 1992, pp. 110-111.
Morrison et al; Experiment Sequence Test Report for Biorack Experiment 01.2-I, “Antigen”; International Microgravity Laboratory Mission No. 2 (IML-2).
Morrison et al; Preliminary Science Report No. 2; IML-2 STS-65; Apr. 21, 1995.
Atassi; Analysis of Electrophoresis Samples and Antibody Applications; Final Progress Report NAS9-18065; Oct. 24, 1995.
Atassi; Analysis of uPA in Supernatants from Kidney Cell Culture Flight Samples; Contract No. NAS9-18065.
Atassi M. Zouhair
Morrison Dennis R.
Ro Theodore U.
Saunders David
The United States of America as represented by the Administrator
LandOfFree
Molecular-specific urokinase antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular-specific urokinase antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular-specific urokinase antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4053615